Cancer therapy resistance: chasing epigenetics

    Access options

    Rent or Buy article

    Get time limited or full article access on ReadCube.

    from$8.99

    All prices are NET prices.

    References

    1. 1

      Knoechel, B. et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat. Genet. 46, 364–370 (2014).

    2. 2

      Sequist, L.V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011).

    3. 3

      Sharma, S.V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69–80 (2010).

    4. 4

      Yao, Z. et al. TGF-b IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc. Natl. Acad. Sci. USA 107, 15535–15540 (2010).

    5. 5

      Weng A.P. et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269–271 (2004).

    6. 6

      Palomero, T. et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat. Med. 13, 1203–1210 (2007).

    7. 7

      Zuber, J. et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524–528 (2011).

    Download references

    Ethics declarations

    Competing interests

    C.R.V. is a consultant for Tensha Therapeutics. The other authors declare no conflict of interest.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Cancer therapy resistance: chasing epigenetics. Nat Med 20, 340–341 (2014) doi:10.1038/nm.3528

    Download citation

    Further reading